Active Pharmaceutical Ingredients

Catalog No. Product Name Information
A2662 Emibetuzumab (Anti-HGFR / c-Met) Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD.
A2668 Etokimab (Anti-IL-33) Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD.
A2991 Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3)) Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3)) is an IgG1 monoclonal antibody targeting αvβ3 integrin. It inhibits angiogenesis and melanoma tumor growth and can be used to research anticancer. MW :144.18 KD.
E0361 Enclomiphene Citrate

Enclomiphene citrate is the trans isomer of clomiphene citrate and acts as a non-steroidal estrogen receptor antagonist.

S8912 Eribulin Mesylate Eribulin Mesylate, an analogue of the marine natural product halichondrin B, is a nontaxane completely synthetic microtubule inhibitor.
E0005 Enfuvirtide Acetate Enfuvirtide Acetate (T20 Acetate, DP178 Acetate) is an HIV fusion inhibitor with ic50s of 13.63  nM and 30.21  nM on infection by HIV-1IIIB in MT-2 cells and HIV-1Bal in M7 cells, respectively.Solutions are unstable and should be fresh-prepared.
S9629 Elacestrant (RAD1901) Dihydrochloride Elacestrant (RAD1901) Dihydrochloride is an orally available selective estrogen receptor degrader (SERD) with IC50 of 48 nM and 870 nM for ERα and ERβ, respectively.
S4929 Enasidenib(AG-221) Mesylate Enasidenib (AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).
S4433 Eliglustat hemitartrate Eliglustat hemitartrate (Genz-112638, Eliglustat tartrate) is a potent, specific and orally active inhibitor of glucosylceramide synthase with IC50 of 24 nM.
S4429 Edoxaban Edoxaban (DU-176b, Savaysa), an antithrombotic agent, is a selective, potent and orally active inhibitor of factor Xa (FXa) with Ki of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively.
S4431 Ertugliflozin L-pyroglutamic acid Ertugliflozin (MK-8835, PF-04971729) L-pyroglutamic acid is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2) with IC50 of 0.877 nM for h-SGLT2. Ertugliflozin has the potential for the treatment of type 2 diabetes mellitus.
S3498 Ecamsule.2Na Ecamsule.2Na is the Sodium salt form of Ecamsule. Ecamsule is an active ingredient of sunscreens that protects the skin from sunburn and erythema.
S9656 Enarodustat (JTZ-951) Enarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia.
S8851 Elexacaftor (VX-445) Elexacaftor (VX-445) is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector.This is a compound which is not chiral purity.
S6676 Ebselen Ebselen (DR 3305, SPI-1005, PZ-51, CCG-39161) is a small-molecule capsid inhibitor of HIV-1 Replication with IC50 of 46.1 nM in TR-FRET assay.
S2001 Elvitegravir Elvitegravir is an HIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively.
S7786 Erlotinib Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
S1250 Enzalutamide Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells. Enzalutamide is shown to increase autophagy.
S4673 Etonogestrel Etonogestrel (Implanon, Nexplanon, 3-Oxodesogestrel, 3-keto-Desogestrel) is a synthetic form of the naturally occurring female sex hormone progesterone. It binds to the cytoplasmic progesterone receptors in the reproductive system and subsequently activates progesterone receptor mediated gene expression.
S7280 Edoxaban tosylate Monohydrate Edoxaban (DU-176b) is a selective factor Xa inhibitor with Ki of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.
  • First Page
  • Last Page